Azathioprine-induced lymphoma manifesting as fulminant hepatic failure.
Azathioprine and rheumatoid arthritis are known to be associated with an increased risk of the development of non-Hodgkin's lymphoma; however, the manifestation of fulminant hepatic failure is extremely uncommon in patients with non-Hodgkin's lymphoma. In this article, we describe a patient with rheumatoid arthritis who was taking azathioprine, in whom fulminant hepatic failure occurred because of massive lymphomatous infiltration of the liver.
Aguilar
H I
HI
Division of Gastroenterology and Internal Medicine, Mayo Clinic Rochester, MN 55905, USA.
Burgart
L J
LJ
Geller
A
A
Rakela
J
J
D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001379:Azathioprine / Q000009:adverse effects* / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury / Q000150:complications / Q000209:etiology*; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000473:pathology; D017728:Lymphoma, Large-Cell, Anaplastic / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000473:pathology; D008875:Middle Aged; D014463:Ultrasonography
D018501:Antirheumatic Agents; D001379:Azathioprine